[1/3] Excited to share that our work was published @NatureComms!
We show that loss of the tumour suppressor gene CUX1 in #AML results in CFLAR-mediated apoptosis inhibition important for AML survival, and establish CFLAR as potential therapeutic target.
https://t.co/fMbtNuHRyf
The #LengerkeLab at the University Hospital Tübingen is seeking a Postdoctoral Fellow to perform cutting-edge research on cellular therapies as well as the immunity of cancer stem cells.
Please, follow the link below to submit your application. 👇
https://t.co/WboqbqVaZb
The #LengerkeLab is searching for a technical assistant. Please, see link below for further information. 👇
We are looking forward to your application!
https://t.co/nxrSemKqNz
Are you interested in how "Recipient sex and donor risk group influence leukemia kinetics in NSG mice"? Then visit our poster 👉P462 to learn more.
https://t.co/P7vzyGVl1f
#LengerkeLab#EHA23
2 days to go too bag yourself a talk slot at the Mol. Hem. Workshop @EHA_Hematology annual meeting in Frankfurt. Excellent platform to showcase your latest science. Apply via the link: https://t.co/77EUOO5O35
My 3 year old daughter Lila was recently diagnosed with a VERY rare and aggressive type of #leukemia.
👉 It’s potentially treatment resistant… AND
👉 Requires a bone marrow transplant.
A🧵with all the details we have so far 👇
Please @Twitter help me save my little girl.
There is an open position for a Postdoctoral Fellow or Senior Scientist (f/m/d) in the #LengerkeLab at @uktuebingen.
Please, follow the link below for more information. https://t.co/yG6CeCj5Ao
Do you want to join the #LengerkeLab? We are looking for a Postdoctoral Fellow or Senior Scientist to work with zebrafish leukemia models in beautiful Tübingen.
Please, apply here👇
https://t.co/RHz0S8EwCu
Bitte RT: Wir suchen Informatiker:innen für HEROES-AYA (https://t.co/yANB93iYPF), ein Verbundprojekt der @XgegenKrebs, das zum Ziel hat, Tumorheterogenität und -evolution bei Kindern und jungen Erwachsenen mit Krebs zu verstehen und gezielt zu behandeln.
https://t.co/TgzQU3mkTa
When you're at #EHA2022, please visit our PhD Student Marlon Arnone at his poster:
"The role of the Mannose Receptor C-Type 2 (MRC2) in leukemic stem cell maintenance in AML."
(Hall D, Friday, June 10, 16:30-17:45 CEST)
https://t.co/GH4h3EU5gJ
Presented this paper in our Journal Club @uktuebingen today. It's excellent work and definitely worth a read!
The conclusions are a game-changer for the treatment of #melanoma patients and likely have wider implications for therapies targeting the MAPK pathway in other #cancers.
On #WorldCancerDay, my former PI @StefanFrohling is rocking his interview (in German)! He answers questions on "What is cancer?" and "How can cancer treatment be improved?". #PersonalizedOncology
https://t.co/0FQPYvScJD
Prime editing can be used to precisely insert short DNA sequences into the genome. But what determines how efficiently any given sequence can be inserted? Joined forces @JulianeWeller, Elin Madli Peets, Ananth Pallaseni, @FabioLib, @LeopoldParts https://t.co/UOpbYDDbyO. A 🧵
My PhD paper is out! Aptamer-mediated transcriptional gene silencing of Foxp3 inhibits regulatory T cells and potentiates antitumor response. This work was developed in @UNICAMP & @CNPEM. @MolTherapy#MTNA. #Treg, #Aptamers, #immunotherapy, #Foxp3. https://t.co/t7uK4Lkosl
Super happy to announce that today I have officially joined Prof Lengerke's lab at the University Hospital Tübingen (@uktuebingen) as a Postdoctoral Fellow. I'm very much looking forward to working with you all!
https://t.co/GS6b2hM6AU